ALPHA RESEARCH INSTITUTE.png

Available

studies

image (3).jpg

Metastatic
Colorectal Cancer

 

It is a type of cancer focused on the digestive tract that occurs for several reasons. Colorectal cancer cells can break away from the original tumor and move through the bloodstream or lymphatic system to other parts of the body, such as the liver, lungs and brain. (cancer.org)

The lifetime risk of colorectal cancer is about 1 in 23 (4.4%) for men and 1 in 25 (4.1%) for women. The risk is slightly lower in women than in men. (cancer.org)

 

Alpha Research is studying this disease to help thousands of people suffering from this condition. Treatment consists of initiating therapy with the drug stimvax®, which already has multiple studies. 

Patients failed on Treatment of Colorectal Cancer, a new treatment option currently under trial Allostim- a formulated T-STIM cells that have been cultured and activated for 4h by adding CD3/CD28 conjugated microbeads. The activated cells are washed and suspended in formulation media and loaded into single dose cryovials. The formulation media contains PlasmaLyteA supplemented with 1% human serum albumin and 2% DSMO. This is a third line drug. Patients 18 to 80 years old with metastatic, histologically confirmed, adenocarcinoma of rectum or colon who have been previously treated with two lines of chemotherapy can be eligible for the study. This Study is completely free of cost including every test and imaging. Feel free to ask more questions about this study.


Voluntary participation will help people suffering from this disease worldwide and will make great contributions to medicine today. 

We are a call or message away from answering all your questions and queries or if you would like to learn more about the study